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SummArY – Prostatic adenocarcinoma (PC) comprises around 19% of malignancies in Croa-
tian male population. On the basis of PSA value, gleason score, grading group and clinical stage, PC 
can be classified into low- and high-risk groups which is significant for different therapeutic regimens 
and prognostic outcomes. in this retrospective study, we analyzed the difference in preoperative PSA 
value in a group of 272 patients who underwent radical prostatectomy and were diagnosed with PC 
adenocarcinoma in our institution in a period from January 1st, 2018 untill december 31st, 2018. Sub-
sequently, they were divided into low- and high-risk prostatic adenocarcinoma groups. Our results 
demonstrated positive correlation in preoperative PSA values between the groups and therefore sup-
port the use of PSA as one of the parameters in defining low- and high-risk prostatic adenocarcinoma 
categories.
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Adenocarcinoma of the prostate (PC) is considered 
to be one of the most common malignancies in male 
population of western society1,2. in developed coun-
tries, the percentage of men suffering from this cancer 
rises up to 15.3 %, while in underdeveloped ones, that 
percentage is much lower3,4. in most cases prostate 
cancer can be considered low-risk and treated success-
fully with therapeutic approaches including active sur-
veillance of the patient, surgery and radiation5. Still, 
cases that can be characterized as a high-risk disease 
should be recognized, since it implies larger mortality 
risk and the possibility of resistance to treatment when 
compared to low-risk cases5,6. gleason score, grade 
groupings, clinical stage and preoperative PSA value 
are important factors in defining these two groups of 
patients suffering from prostate adenocarcinoma. The 
aim of this study was to analyze the correlation in pre-
operative PSA value between low- and high-risk 
group patients diagnosed with prostatic adenocarci-
noma.
Patients and methods
The study included 272 patients, median age of 
64.7 years (range 40 - 78 years), treated with radical 
retropubic prostatectomy for prostatic adenocarcino-
ma at the department of urology in Sestre milosrd-
nice university hospital Centre in Zagreb, Croatia. 
The diagnosis of prostatic adenocarcinoma was estab-
lished on needle core biopsies and confirmed by he 
slides examination of radical prostatectomy specimens 
in all cases. data on PSA preoperative values, gleason 
score and clinical stage were collected from database of 
ljudevit Jurak department of Pathology and Cytolo-
gy, and dpt of urology, Sestre milosrdnice university 
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hospital Centre, Zagreb, Croatia. Patients were di-
vided into low- and high-risk prostatic adenocarcino-
ma category based on national Comprehensive Can-
cer network (nCCn) criteria for definition of high-
grade prostatic adenocarcinoma (PSA ≥ 20 ng/ml or 
biopsy gleason sum 8-10 or clinical stage ≥ t3 or any 
2 of the following: t2b/c, biopsy gleason sum 7, PSA 
10-20 ng/ml) 6.
Statistical analysis was performed using mann-
whitney u test. results were considered statistically 
significant in cases of p value < 0.05.
Results
gleason score was under 7 in 10 (3,7%) patients, 
while 230 (84,6%) patients had a score 7, yet 169 
(62,1%) patients had a score 7 (3+4), while 61 (22,4%) 
had a score 7 (4+3). gleason score 8 was recorded in 14 
(5,1%) patients with 4 (1,5%) of them having 4+4, 7 
(2,6%) having a score 3+5 and 3 (1%) had a score 5+3. 
eighteen patients had a score 9 (6.6%), with 15 (5.5%) 
having a score 4+5, and 3 (1,1%) a score 5+4. in stage 
t2 were 222 patients, with 16 of them in stage 2a, and 
206 in t2c, while 50 patients were in t3 clinical stage 
(table 1). low-risk group consisted of 183 (67.3%) 
patients, while high-risk group had 89 (32.7%) pa-
tients. range of PSA was 0.79- 92.6 ng/ml, in low-
risk group 0.79- 19.22 ng/ ml, median value 14.7 ng/
ml and in high-risk group 3.4 - 92.6 ng/ml, with a 
median value of 25.5 ng/ml. we demonstrated posi-
tive correlation of preoperative PSA value between 
low- and high-risk group; patients with low-risk pros-
tatic adenocarcinoma had smaller values of preopera-
tive PSA than patients in the high-risk group (p < 
0.01, p< 0.05) (table 2).
Discussion
Prostatic cancer is among the most common vis-
ceral malignancies in male population, including Cro-
atia1,7. men with family history of prostate carcinoma, 
those with inherited BrCA1 and 2 mutations and 
men of black race are considered to be more suscepti-
ble to development of this disease2. it can demonstrate 
heterogeneity in its clinical behavior, ranging from in-
dolent to aggressive disease characterized by metastat-
ic and potentially lethal disease resistant to therapy8. 
Therefore, risk stratification of patients with this ma-
lignancy is necessary for the right therapeutic ap-
proach to be applied8. Currently, different criteria for 
risk stratification are used8. most patients are diag-
nosed with low-risk disease, however, up to 15% of 
diagnosed cases are high-risk9. determining a patient’s 
disease risk is important when choosing adequate 
treatment option and therefore achieve best prognostic 
outcome possible9,10.
Current definitions regarding risk assessment in-
volve gleason grading as an important factor that has 
over the years become relevant in determining high-
risk disease, which has great significance in clinical 
settings for predicting prognosis of the disease. in ad-
dition, gleason score has important impact on thera-
peutic approach to the patient, assisting in deciding 
whether radical method or just active surveillance of 
the patient should be applied11,12. Study of Berney et 
al.10 demonstrated that patients with gleason score 6 
(3+3) require only surveillance, but also that patients 
with a score 7 (3+4) and minimal percentage of pattern 
4 have a good prognosis. The same authors emphasized 
the importance of pattern 4 and 5 percentage affecting 
therapeutic measures, since their presence implicates 
Table 2. Number of patients and median value  
of preoperative PSA value in low- and high-risk group  










14.7 ng/ml 25.5 ng/ml P < 0.01
Table 1. Gleason score and clinical stage T of evaluated 
patients
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worse prognosis10. kamel et al showed that patients 
with gleason score 7 (4+3) prostate cancers have high-
er PSA levels at diagnosis than those with 7 (3+4).13
PSA still holds an important place in risk assess-
ment and prostate carcinoma management consider-
ing its role in the process of disease screening, estima-
tion of future disease appearance, recurrent disease or 
occult metastatic disease detection and in the process 
of disease management2. PSA is commonly detected 
in blood as total prostate specific antigen (tPSA) and 
usually increases in the presence of prostatic malignant 
disease3. however, PSA level increase is not specific for 
prostatic carcinoma, since it can occur due to prostati-
tis and benign prostatic hyperplasia, which are benign 
conditions by nature3. increase in PSA is according to 
international Society of urological Pathology an im-
portant point in diagnosis of prostate carcinoma, yet 
not solely sufficient for prognosis and estimation of 
disease progression14. Currently, the value of PSA 20 
ng/ml or more has been used as a cut-off for defining 
high-risk category patients, yet, its value cannot be 
used as the only factor in risk assessment due to lack of 
specificity. however, in combination with other pa-
rameters such as gleason score and clinical stage, it 
has great value in prostate cancer risk assessment15. 
Our study also demonstrated the importance of pre-
treatment PSA value, since levels were significantly 
higher in high-risk than in low-risk patient groups.
Another important factor for defining risk groups 
of prostatic carcinoma is the clinical stage. Contempo-
rary definitions for high-risk cancer include clinical 
stage t2b or higher in combination with pretreatment 
PSA and gleason score; however, standardized defini-
tion has still not been established15.
definitions of high-risk disease are not only het-
erogeneous, but also associated with differences in 
prognostic outcome8. mossanen et al. demonstrated 
significant differences in the outcome in patients de-
pending which criteria for high-risk disease were ap-
plied before treatment5. in case of patients with high-
risk disease, optimal treatment is still debatable, but 
the options currently include radical prostatectomy, 
androgen deprivation therapy combined with external 
beam radiotherapy or a combination of androgen de-
privation therapy with external beam radiotherapy and 
brachytherapy6. As for the low-risk group, roy et al. 
demonstrated no significant difference in survival 
among patients with low-risk cancer when compared 
to those treated with active surveillance and those un-
dergoing active treatment16.
in conclusion, we emphasize the importance of risk 
assessment in prostate adenocarcinoma patients. in 
addition, our study demonstrated positive correlation 
of pretreatment PSA value with the high-risk group as 
defined by national Comprehensive Cancer network 
(nCCn) criteria, therefore supports its use as one of 
the parameters in the estimation of risk. further stud-
ies with correlation of grade groups and preoperative 
PSA values may also be informative.
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Sažetak
vriJednOSti PrOStAtA SPeCifiČnOg AntigenA (PSA)  
u BOleSnikA S AdenOkArCinOmOm PrOStAte niSkOg i viSOkOg riZikA
S. Mašić, I. Pezelj i B. Krušlin
Adenokarcinom prostate čini oko 19% maligniteta u muškoj populaciji hrvata. Svi dijagnosticirani adenokarcinomi 
prostate se s obzirom na vrijednost PSA, gleason zbroj i klinički stadij mogu svrstati u skupine niskog i visokog rizika. u 
ovoj retrospektivnoj studiji analizirali smo razliku u vrijednostima preoperativnog PSA u skupini od 272 pacijenta kojima je 
dijagnosticiran adenokarcinom prostate nakon radikalne prostatektomije učinjene u našoj ustanovi u razdoblju od jedne 
godine (01. siječnja do 31. prosinca 2018.), a koji su podijeljeni u skupine adenokarcinoma prostate niskog i visokog rizika. 
rezultati naše studije pokazuju pozitivnu korelaciju u vrijednostima preoperativnog PSA između grupa. nadalje, rezultati 
naše analize podupiru upotrebu PSA kao jednog od parametara u definiranju kategorija niskog i visokog rizika karcinoma 
prostate.
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